Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$15.33 USD
+0.81 (5.54%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $15.32 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARQT 15.33 +0.81(5.54%)
Will ARQT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ARQT
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings
Arcutis Biotherapeutics (ARQT) Anticipates Strong Q2 Earnings Growth
Arcutis Biotherapeutics Q2 2025 Earnings Preview
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion
Franklin Biotechnology Discovery Fund Q2 2025 Commentary